Inhibikase Therapeutics Stock Revenue
| IKT Stock | USD 2.34 0.03 1.30% |
Inhibikase Therapeutics fundamentals help investors to digest information that contributes to Inhibikase Therapeutics' financial success or failures. It also enables traders to predict the movement of Inhibikase Stock. The fundamental analysis module provides a way to measure Inhibikase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibikase Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 260.5 K | 247.5 K |
Inhibikase | Revenue |
Inhibikase Therapeutics Company Revenue Analysis
Inhibikase Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Inhibikase Therapeutics Revenue | 260.5 K |
Most of Inhibikase Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibikase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Inhibikase
Projected quarterly revenue analysis of Inhibikase Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Inhibikase Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Inhibikase Therapeutics' stock price.
Inhibikase Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Inhibikase Therapeutics is extremely important. It helps to project a fair market value of Inhibikase Stock properly, considering its historical fundamentals such as Revenue. Since Inhibikase Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibikase Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibikase Therapeutics' interrelated accounts and indicators.
| -0.87 | 0.48 | -0.45 | -0.47 | -0.62 | ||
| -0.87 | -0.41 | 0.6 | 0.57 | 0.75 | ||
| 0.48 | -0.41 | -0.84 | -0.26 | -0.29 | ||
| -0.45 | 0.6 | -0.84 | 0.42 | 0.51 | ||
| -0.47 | 0.57 | -0.26 | 0.42 | 0.51 | ||
| -0.62 | 0.75 | -0.29 | 0.51 | 0.51 |
Click cells to compare fundamentals
Inhibikase Revenue Historical Pattern
Today, most investors in Inhibikase Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Inhibikase Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Inhibikase Therapeutics revenue as a starting point in their analysis.
Inhibikase Therapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Inhibikase Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Inhibikase Therapeutics reported 260.5 K of revenue. This is 100.0% lower than that of the Biotechnology sector and 99.96% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Inhibikase Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibikase Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inhibikase Therapeutics could also be used in its relative valuation, which is a method of valuing Inhibikase Therapeutics by comparing valuation metrics of similar companies.Inhibikase Therapeutics is currently under evaluation in revenue category among its peers.
Inhibikase Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inhibikase Therapeutics from analyzing Inhibikase Therapeutics' financial statements. These drivers represent accounts that assess Inhibikase Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inhibikase Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 102.5M | 55.7M | (13.7M) | (1.8M) | (2.0M) | (1.9M) |
Inhibikase Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibikase Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibikase Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Inhibikase Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Inhibikase Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inhibikase Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inhibikase Therapeutics' value.| Shares | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Redmond Asset Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 626.5 K | Blair William & Co | 2024-06-30 | 116.1 K | Geode Capital Management, Llc | 2024-09-30 | 50.1 K | Renaissance Technologies Corp | 2024-09-30 | 19.9 K | Vanguard Group Inc | 2024-09-30 | 16.7 K | State Street Corp | 2024-06-30 | 10.1 K |
Inhibikase Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (238.85) % | ||||
| Current Valuation | 154.13 M | ||||
| Shares Outstanding | 67.19 M | ||||
| Shares Owned By Insiders | 10.46 % | ||||
| Shares Owned By Institutions | 11.62 % | ||||
| Number Of Shares Shorted | 187.95 K | ||||
| Price To Book | 26.46 X | ||||
| Price To Sales | 1,976 X | ||||
| Revenue | 260.5 K | ||||
| Gross Profit | (8.26 M) | ||||
| EBITDA | (19.91 M) | ||||
| Net Income | (19.03 M) | ||||
| Cash And Equivalents | 32.21 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 622 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.56 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 157.23 M | ||||
| Total Asset | 14.51 M | ||||
| Retained Earnings | (66.9 M) | ||||
| Working Capital | 10.77 M | ||||
| Net Asset | 14.51 M |
About Inhibikase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibikase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.